Kite (Gilead) Enters Strategic Collaboration and Equity Investment in Arcellx to Co-develop and Co-commercialise CART-ddBCMA

PAI Partners and KIRKBI A/S Acquire Armacell from Blackstone

December 4, 2019

Manufacturing

PAI Partners and KIRKBI A/S have agreed to acquire Armacell from private equity funds managed by Blackstone, with PAI becoming the majority shareholder and KIRKBI increasing its stake to a significant minority. Armacell is a Luxembourg-headquartered manufacturer of flexible and engineered foams with 24 manufacturing facilities and over 3,000 employees; CEO Patrick Mathieu will remain in place. Terms are confidential and subject to regulatory approvals, and the buyers plan to support Armacell's growth, product innovation and global expansion.

Thomas H. Lee Partners Leads $100M Series D Investment in FourKites

March 24, 2021

Transportation

Thomas H. Lee Partners (THL) led a $100 million Series D growth round in FourKites, a Chicago-based real-time supply chain visibility software provider. Strategic investors Zebra Technologies, Volvo Group Venture Capital and Qualcomm Ventures joined the financing to help FourKites accelerate product innovation, expand market penetration and pursue organic and inorganic growth initiatives.

NLS Pharmaceutics Merges with Kadimastem to Form NewCelX

June 27, 2025

Biotechnology

NLS Pharmaceutics Ltd. completed a $3.0 million equity financing to support its pending merger with Kadimastem Ltd.; the transaction closed and the combined company was re-named NewCelX Ltd. The deal brings together NLS's CNS-focused pipeline and Kadimastem's cell therapy programs (AstroRx and IsletRx) to advance clinical development for ALS, diabetes and other regenerative-medicine indications.

kdc/one Acquires Aerofil Technology; KKR Makes Strategic Investment in kdc/one

March 30, 2022

Manufacturing

Knowlton Development Corporation (kdc/one) acquired Aerofil Technology, a Sullivan, Missouri-based aerosol and liquid contract packager, adding North American aerosol filling capabilities to its network. Simultaneously, global investment firm KKR made a strategic minority investment in kdc/one to support the company's continued growth alongside existing investor Cornell Capital.

NewcelX (f/k/a NLS Pharmaceutics) Completes Merger with Kadimastem Ltd.

October 30, 2025

Biotechnology

NewcelX Ltd. (f/k/a NLS Pharmaceutics) completed a merger with Kadimastem Ltd., effective October 30, 2025, forming a combined biotechnology company that will trade on the Nasdaq Capital Market under the ticker "NCEL" starting October 31, 2025. Under the merger, Kadimastem shareholders received 0.706 NewcelX shares per Kadimastem share; the combined company will advance cell‑therapy and small‑molecule programs (including AstroRx and IsletRx) with headquarters in Zurich and R&D operations in Ness Ziona, Israel.

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.